

CS/NSE/PR/2014-2015
May 22, 2014

To
The Manager – Listing Department,
National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Dear Sir/Madam,

Scrip Code – SUVEN-EQ

Sub: 1) Notification of Audited Financial Results for the financial year ended 31st March 2014 – Clause 41

2) Dividend Recommendation – Clause 20

3) Closure of Register of Members & Share Transfer Books - Clause-16

1) Notification of Audited Financial Results for the financial year ended 31st March 2014-Clause 41 and other information

We are forwarding herewith Audited Financial Results for the financial year 2013-2014, in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Annual Audited financial results for the financial year 2013-2014 in its meeting held today i.e. 22nd May, 2014 and Auditor’s Report of the Company.

Brief Financials as required to be furnished under clause 20 are as follows:

Particulars		2013-14 ₹ Lakhs	2011-12 ₹ Lakhs
(i).	Revenue from operations	51031.24	25788.46
(ii).	Operating expenditure	29125.39	20469.90
(iii).	Depreciation and amortization	883.73	786.72
(iv).	Operating profit	21022.12	4531.84
(v).	Interest expense	1051.28	1350.94
(vi).	Other income	302.95	104.34
(vii).	Profit before Tax	20273.79	3285.24
(viii).	Provision for Tax	5858.03	201.29
(ix).	Profit for the year	14415.76	3083.95
(x).	Balance brought forward from previous year	6069.00	3705.12

SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Corporate Identity Number: L24110AP1989PLC009713
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com, www.suven.com

(xi).	Profit available for appropriation	20484.77	6789.07
	Appropriations:		
(xii).	Proposed final dividend	2920.72	350.49
(xiii).	Tax on dividend	496.40	59.58
(xiv).	Transfer to General Reserve	1450.00	310.00
(xv).	Balance carried to balance sheet	15617.65	6069.00

2) Dividend Recommendation – Clause 20

The Board has proposed a Dividend of Re. 0.50 per share (50% of face value Rs. 1.00 each), with an additional Special Silver Jubilee year dividend of Rs. 2.00 per share (200% of face value of Rs. 1.00 each), aggregating to Rs 2.50 per share for the financial year 2013-14, the dividend will be paid on and from 26th August, 2014 to the members as on book closure date, subject to the approval of Members in the ensuing Annual General Meeting.

3) Closure of Register of Members & Share Transfer Books - Clause-16


Pursuant to clause 16 of the Listing agreement, we hereby notify the Book Closure dates for the Register of members and Share Transfer as under.

Security Code	Type of Security & Paid-up value	Book-Closure		Purpose
		From	To	
SUVEN/ 530239	Equity Shares Rs 1.00 each	26/07/2014	29/07/2014	AGM & Dividend Declaration
		(both days inclusive)		

The Annual General Meeting of the Company will be held on Tuesday the 12th day of August 2014

Please find enclosed Press release of our company. We request you to take these documents on your records.

Thanking You,
Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**


K HANUMANTHA RAO
Company Secretary

SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Corporate Identity Number: L24110AP1989PLC009713
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com, www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110AP1989PLC009713

STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FOR THE YEAR ENDED 31/03/2014

PART - I		Rs. in lakhs				
Sl. No.	PARTICULARS	Quarter ended			Year to date figures	Previous year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
		Audited	Un-audited	Audited	Audited	Audited
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	13,080.34	11,942.71	7,470.36	51,031.24	25,788.46
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net) (a)+(b)	13,080.34	11,942.71	7,470.36	51,031.24	25,788.46
2	Expenses					
	a) Cost of materials consumed	3,898.42	3,576.20	2,634.47	15,049.65	8,827.40
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	339.57	(1,024.28)	185.25	(1,397.66)	(559.63)
	d) Employee benefits expense	710.62	893.97	554.62	3,144.21	2,537.70
	e) Depreciation and amortisation expense	227.51	224.83	214.43	883.74	786.72
	f) Other expenses - Manufacturing Expenses	1,600.29	1,340.82	1,147.76	5,388.94	3,904.81
	- R & D Expenses	1,238.05	973.08	982.12	4,794.79	3,469.32
	- Others	549.70	694.40	606.92	2,145.45	2,290.30
	Total expenses	8,564.16	6,679.02	6,325.57	30,009.12	21,256.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,516.18	5,263.69	1,144.79	21,022.12	4,531.84
4	Other Income	120.29	84.96	54.29	302.95	104.34
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	4,636.47	5,348.65	1,199.08	21,325.07	4,636.18
6	Finance costs	169.51	221.43	270.74	1,051.28	1,350.94
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	4,466.96	5,127.22	928.34	20,273.79	3,285.24
8	Exceptional Items	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 + 8)	4,466.96	5,127.22	928.34	20,273.79	3,285.24
10	Tax Expenses	1,226.40	1,483.90	65.30	5,858.04	201.29
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	3,240.56	3,643.32	863.04	14,415.75	3,083.95
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	3,240.56	3,643.32	863.04	14,415.75	3,083.95
14	Share of profit / (loss) of associates	-	-	-	-	-
15	Minority interest	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	3,240.56	3,643.32	863.04	14,415.75	3,083.95
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,168.29	1,168.29	1,168.29	1,168.29	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	25,276.34	14,277.70
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	2.77	3.12	0.74	12.34	2.64
	b) Diluted	2.77	3.12	0.74	12.34	2.64
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	2.77	3.12	0.74	12.34	2.64
	b) Diluted	2.77	3.12	0.74	12.34	2.64


PART - II		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
A	PARTICULARS OF SHAREHOLDING	Audited	Un-audited	Audited	Audited	Audited
1	Public share holdings					
	a. Number of shares	41,171,212	41,171,212	41,993,960	41,171,212	41,993,960
	b. Percentage of share holding	35.24%	35.24%	35.94%	35.24%	35.94%
2	Promoters and promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered					
	- Number of shares	75,657,576	75,657,576	74,834,828	75,657,576	74,834,828
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	64.06%	64.76%	64.06%
Particulars		3 months ended (31/03/2014)				
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	-				
	Received during the quarter	31				
	Disposed of during the quarter	30				
	Remaining unresolved at the end of the quarter	1				

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						Rs. in lakhs
	PARTICULARS	Quarter ended			Year to date figures	Previous year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
		Audited	Un-audited	Audited	Audited	Audited
1	SEGMENT REVENUE					
	a) Manufacturing (CRAMS)	12,683.57	11,229.62	6,484.41	49,344.00	24,456.23
	b) Services (DDDSS)	396.78	713.08	985.96	1,687.24	1,332.24
	c) Research & Development	-	-	-	-	-
	Net sales/income from operations	13,080.35	11,942.70	7,470.37	51,031.24	25,788.47
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)					
	a) Manufacturing (CRAMS)	5,937.20	6,327.79	2,112.34	26,308.56	9,176.71
	b) Services (DDDSS)	200.73	459.14	258.94	888.72	370.00
	c) Research & Development	(1,238.05)	(973.08)	(982.12)	(4,794.79)	(3,469.32)
	TOTAL	4,899.88	5,813.85	1,389.16	22,402.49	6,077.39
	Less: (i) Interest	89.44	117.92	172.97	618.92	1,174.34
	(ii) Other Un-allocable expenses net off	343.47	568.71	287.84	1,509.78	1,617.81
	(iii) un-allocable Income	-	-	-	-	-
	Profit Before Tax	4,466.97	5,127.22	928.35	20,273.79	3,285.24
3	CAPITAL EMPLOYED (Segment Assets - Segment Liabilities)					
	a) Manufacturing (CRAMS)	19,509.25	21,824.86	12,823.28	19,509.25	13,212.39
	b) Services (DDDSS)	3,493.63	3,367.54	3,053.52	3,493.63	3,093.23
	c) Research & Development	1,815.26	2,136.36	2,412.64	1,815.26	2,503.65
	d) Net assets which are not segmented and used commonly	1,626.50	(707.60)	3,574.87	1,626.50	(3,363.29)
	TOTAL	26,444.64	26,621.16	21,864.31	26,444.64	15,445.98

Notes:

- The above audited results were approved and taken on record at the Board of Directors' Meeting held on 22nd May, 2014.
- Previous years figures have been regrouped/reclassified whenever necessary.
- The figures of the last quarter are the balancing figures between audited figures in respect of full year and un-audited declared upto 3rd quarter ending.
The Board has proposed a Dividend of Re. 0.50 per share (50% of face value Rs. 1.00 each), with an additional Special Silver Jubilee year dividend of Rs. 2.00 per share
- (200% of face value of Rs. 1.00 each), aggregating to Rs 2.50 per share for the financial year 2013-14, subject to approval of the shareholders in the ensuing Annual General Meeting.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO

Place : Hyderabad
Date : 22nd May, 2014

We Deliver




SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034

CIN: L24110AP1989PLC009713

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. In lakhs)

	Particulars	Year ended	
		31/03/2014	31/03/2013
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,168.29	1,168.29
	(b) Reserves and Surplus	25,276.34	14,277.69
	Sub-total - Shareholders' funds	26,444.63	15,445.98
2	Non-current liabilities		
	(a) Long-term borrowings	3,772.92	6,418.33
	(b) Deferred tax Liability (net)	2,759.66	-
	(c) Long-term provisions	179.36	157.78
	Sub-total - Non-current liabilities	6,711.94	6,576.11
3	Current liabilities		
	(a) Short-term borrowings	2,855.36	2,782.59
	(b) Trade payables	4,090.05	3,613.53
	(c) Other current liabilities	4,751.84	3,611.53
	(d) Short-term provisions	3,808.90	731.61
	Sub-total - Current liabilities	15,506.15	10,739.26
	TOTAL - EQUITY AND LIABILITIES	48,662.72	32,761.35
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	19,205.41	16,566.30
	(b) Non-current investments	0.15	0.15
	(c) Deferred tax assets (net)	-	1,569.62
	(d) Long-term loans and advances	1,258.74	939.22
	Sub-total - Non-current assets	20,464.30	19,075.29
2	Current assets		
	(a) Current investments	3.64	7.12
	(b) Inventories	7,862.87	5,381.43
	(c) Trade receivables	6,547.03	2,377.76
	(d) Cash and cash equivalents	6,939.96	2,183.30
	(e) Short-term loans and advances	6,809.17	3,716.77
	(f) Other current assets	35.75	19.68
	Sub-total - Current assets	28,198.42	13,686.06
	TOTAL - ASSETS	48,662.72	32,761.35
For Suven Life Sciences Ltd  Venkat Jasti Chairman & CEO			



**Auditor's Report on Quarterly Financial Results and Year to Date Results of
M/s Suven Life Sciences Limited Pursuant to the Clause 41 of the Listing Agreement**

To
Board of Directors of **M/s. Suven Life Sciences Limited**

We have audited the quarterly financial results of **M/s. Suven Life Sciences Limited** for the quarter ended 31st March, 2014 and the year to date results for the period 1st April, 2013 to 31st March, 2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2014 as well as the year to date results for the period from 1st April 2013 to 31st March 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For **KARVY & CO.**
Chartered Accountants
Firm's Regn.No. 001757S

(K. AJAY KUMAR)
P A R T N E R
(M. No. 021989)



Place: Hyderabad
Date: 22-05-2014